MC-Rx
Powered by ProCare Rx

Fuzeon® enfuvirtide Injection

Ticket #: _____ **Request Date:** _____ **Request Time:** _____

PHYSICIAN CERTIFICATION PRIOR AUTHORIZATION FORM

A request for the patient identified below has been made for the dispensing of **Fuzeon®** enfuvirtide Injection. Based on recent clinical information, we require more information before this prescription can be paid by the patient's health benefit plan. Please fill out the following information and return to us as indicated below:

A. Member Information			
Patient Name:		Plan Name/Plan ID:	
Patient ID:		Patient Date of Birth:	Patient Contact Phone #:

B. Physician Information			
Physician Name:	Physician Address:		
Physician DEA #:	Physician Phone #:	Physician Fax #:	
Drug Name and Strength:	Direction (SIG):	QTY and Days Supply:	NDC #:

C. Pharmacy Information			
Pharmacy Name:	NABP #:	Pharmacy Phone #:	Pharmacy Fax #:

D. Clinical Information (Please fill out the following information: circle all that apply)

Drug: _____ Quantity: _____

Length of Therapy on Prescription: _____ Dosage and Frequency of Dosing: _____

1. ☐ Initiation of therapy OR ☐ Continuation of Therapy
2. Has the patient had a genotype/phenotype completed? (A copy of test results must be submitted for initial therapy.) YES NO
   Date: _____/_____/20_____
3. Has the patient had a viral load completed in the past 6 months? (A copy of lab results must be submitted.) YES NO
   Date: _____/_____/20_____
4. Has the patient had a CD4 count completed in the past 6 months? (A copy of lab results must be submitted.) YES NO
   Date: _____/_____/20_____
5. Has the patient been compliant with previous therapy? YES NO

Authorized Medical Signature:	
Telephone:	**Date:**

When Completed Return To:

MC-Rx Clinical Division, 1267 Professional Parkway, Gainesville, GA 30507
1-866-965-Drug (3784) / Fax # 866-999-7736

**Please note that this form is to be completed by the prescribing physician. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). HIPAA does restrict the communication of PHI with providers for TPO related purposes.